Did you mean velneperit of s 2009 of ベルネペリット?
Displaying drugs 4551 - 4575 of 10619 in total
1-Hydroxy-1-Thio-Glycerol
Experimental
Esreboxetine
Esreboxetine has been used in trials studying the treatment and basic science of Fibromyalgia.
Investigational
Matched Iupac: … (2S)-2-[(S)-(2-ethoxyphenoxy)(phenyl)methyl]morpholine …
Matched Description: … Esreboxetine has been used in trials studying the treatment and basic science of Fibromyalgia. …
Matched Description: … Esreboxetine has been used in trials studying the treatment and basic science of Fibromyalgia. …
2-oxopropyl-CoM
Experimental
6-(2-phenoxyethoxy)-1,3,5-triazine-2,4-diamine
Experimental
Nomacopan
Nomacopan is under investigation in clinical trial NCT03427060 (Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms).
Investigational
Matched Categories: … Recombinant Protein Inhibitor of Complement Factor 5 …
Etryptamine
In the 1960's, alpha-ethyltryptamine (αET), a non hydrazine reversible monoamine oxidase inhibitor, was developed in the United States by the Upjohn chemical company for use as an antidepressant. αET was an FDA approved antidepressant under the name Monase. However, in 1962, after the discovery of an unacceptable incidence of agranulocytosis,...
Illicit
Investigational
Withdrawn
Matched Description: … Substances, after an increasing incidence of its use as a recreational drug in the 1980's. ... In the 1960's, alpha-ethyltryptamine (αET), a non hydrazine reversible monoamine oxidase inhibitor, was ... However, in 1962, after the discovery of an unacceptable incidence of agranulocytosis, the development …
Bebtelovimab
Bebtelovimab (LY-COV1404, LY-3853113) is a human monoclonal antibody approved for emergency use in the treatment of COVID-19. It binds to a portion of the SARS-CoV-2 spike (S) protein's receptor-binding domain, thereby preventing spike protein interaction with ACE2 and subsequent viral entry into host cells. Bebtelovimab is notable in that the...
Investigational
Withdrawn
Matched Description: … It binds to a portion of the SARS-CoV-2 spike (S) protein's receptor-binding domain, thereby preventing ... (LY-COV1404, LY-3853113) is a human monoclonal antibody approved for emergency use in the treatment of ... its expected reduced activity against certain emerging Omicron subvariants of SARS-CoV-2. …
Brecanavir
Brecanavir (VX-385) an orally active aspartic protease inhibitor (PI), under investigation by Vertex and GlaxoSmithKline for the treatment of HIV. In July 2006, Vertex indicated that it expected GSK to initiate phase III trials of the drug in 2007. In December of 2006 GSK announced a decision to discontinue the...
Investigational
Matched Description: … In July 2006, Vertex indicated that it expected GSK to initiate phase III trials of the drug in 2007. ... of HIV. ... In December of 2006 GSK announced a decision to discontinue the development of brecanavir for the treatment …
VGA039
VGA039 is an IgG4 monoclonal antibody directed against protein S.
Investigational
Matched Description: … VGA039 is an IgG4 monoclonal antibody directed against protein S. …
Cibacron Blue
Experimental
Exebacase
Exebacase is under investigation in clinical trial NCT03163446 (Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia).
Investigational
Matched Description: … Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia). ... Exebacase is under investigation in clinical trial NCT03163446 (Safety, Efficacy and Pharmacokinetics of …
2-(3-OXO-PROPYLSULFANYLCARBONYL)-ETHANETHIOLATE
Experimental
Redasemtide
Redasemtide is under investigation in clinical trial NCT05953480 (A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke).
Investigational
Matched Description: … Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke). ... Redasemtide is under investigation in clinical trial NCT05953480 (A Phase 2b, Randomized, Double-blind Study of …
Lumiliximab
Lumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug. It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody, for the potential treatment of allergic conditions. Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for...
Investigational
Matched Description: … Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007. ... antibody, for the potential treatment of allergic conditions. ... It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE …
Tribenuron Methyl
Experimental
REP8839
REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).
Investigational
Matched Description: … MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of …
Levodropropizine
Levodropropizine is under investigation in clinical trial NCT01573663 (A Drug-Drug Interaction Study of Ambroxol and Levodropropizine).
Investigational
Matched Description: … Levodropropizine is under investigation in clinical trial NCT01573663 (A Drug-Drug Interaction Study of …
Matched Products: … DROPOLEV-S 30 MG/5 ML ŞURUP …
Matched Products: … DROPOLEV-S 30 MG/5 ML ŞURUP …
Enoxolone
Enoxolone (glycyrrhetic acid) has been investigated for the basic science of Apparent Mineralocorticoid Excess (AME).
Investigational
Matched Description: … Enoxolone (glycyrrhetic acid) has been investigated for the basic science of Apparent Mineralocorticoid …
Matched Categories: … Preparations for Treatment of Wounds and Ulcers …
Matched Categories: … Preparations for Treatment of Wounds and Ulcers …
Displaying drugs 4551 - 4575 of 10619 in total